RespireRx Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This report of RespireRx Pharmaceuticals Inc uses information from across the web as well as from public filings by RespireRx Pharmaceuticals Inc. This webpage of RespireRx Pharmaceuticals Inc was assembled by All Street Sevva using proprietary artificial intelligence. This page contains a questions and answers section on RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.2; made up of an environmental score of 8.0, social score of 2.7 and governance score of 8.0.
6.2
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
427 | Scancell Holdings PLC | 6.3 | High |
427 | Verastem Inc | 6.3 | High |
450 | RespireRx Pharmaceuticals Inc | 6.2 | High |
450 | Cannasouth Ltd | 6.2 | High |
450 | CareDx International AB | 6.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does RespireRx Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does RespireRx Pharmaceuticals Inc disclose current and historical energy intensity?
Does RespireRx Pharmaceuticals Inc report the average age of the workforce?
Does RespireRx Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does RespireRx Pharmaceuticals Inc disclose its ethnicity pay gap?
Does RespireRx Pharmaceuticals Inc disclose cybersecurity risks?
Does RespireRx Pharmaceuticals Inc offer flexible work?
Does RespireRx Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does RespireRx Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does RespireRx Pharmaceuticals Inc conduct supply chain audits?
Does RespireRx Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does RespireRx Pharmaceuticals Inc conduct 360 degree staff reviews?
Does RespireRx Pharmaceuticals Inc disclose the individual responsible for D&I?
Does RespireRx Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does RespireRx Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does RespireRx Pharmaceuticals Inc disclose water use targets?
Does RespireRx Pharmaceuticals Inc have careers partnerships with academic institutions?
Did RespireRx Pharmaceuticals Inc have a product recall in the last two years?
Does RespireRx Pharmaceuticals Inc disclose incidents of discrimination?
Does RespireRx Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has RespireRx Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does RespireRx Pharmaceuticals Inc disclose parental leave metrics?
Does RespireRx Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does RespireRx Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does RespireRx Pharmaceuticals Inc disclose the pay ratio of women to men?
Does RespireRx Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does RespireRx Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does RespireRx Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is RespireRx Pharmaceuticals Inc involved in embryonic stem cell research?
Does RespireRx Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does RespireRx Pharmaceuticals Inc disclose its waste policy?
Does RespireRx Pharmaceuticals Inc report according to TCFD requirements?
Does RespireRx Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does RespireRx Pharmaceuticals Inc disclose energy use targets?
Does RespireRx Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does RespireRx Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for RespireRx Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.